Abstract:The past year has offered significant advancements in the field of non–small cell lung cancer (NSCLC), both in the early and advanced disease settings. The identification of guideline‐recommended actionable targets has provided the foundation for developing multiple new therapeutic agents. There has been a focus on developing drugs designed to overcome acquired resistance, a limitation of tyrosine kinase inhibitor–based therapy in lung cancer. In addition, there is an emerging trend toward combination therapies for patients in the first‐line setting with the goal of preventing or delaying resistance. Another promising area of development has been the use of antibody–drug conjugates, where there are the initial reports of central nervous system efficacy and activity in patients with genomic alterations. Over the past year, numerous publications and presentations have highlighted multiple therapeutic advances, offering new treatment options for patients with NSCLC. The focus of this review is to summarize the most impactful findings, emphasizing their significance in the evolving treatment landscape for NSCLC. Several landmark trials in lung cancer with practice‐changing clinical implications have been presented and published in 2023. This article reviews a selection of these trials as they relate to early and advanced‐stage oncogene‐driven lung cancer. The ADAURA and ALINA trials, in which targeted therapy given in the adjuvant setting has demonstrated improved clinical outcomes, are reviewed. In the advanced‐stage setting, recent trials in the context of specific oncogene drivers are reviewed, including EGFR, ALK, ROS1, RET, ERBB2 (HER2), BRAF, MET exon 14 skipping (METex14), and KRAS alterations. Also discussed are the results of several trials that have evaluated the use of combination therapies and resistance‐mechanism agnostic treatment strategies. Plain Language Summary Targeted therapy plays an important role for patients with early and advanced‐stage non–small cell lung cancer carrying specific genetic alterations. New strategies that combine multiple therapies are now being studied in randomized clinical trials, with the goal of enhancing the effectiveness of targeted therapy for patients with advanced lung cancer.

Targeted Therapy for Metastatic Non–Small Cell Lung Cancer

New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2

Targeted therapeutic options in early and metastatic NSCLC-overview

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches

Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer

Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion

Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer

Top advances of the year: Targeted therapy for lung cancer

Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer

Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers

[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)]

Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer

Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future

Emerging Targets in Non-Small Cell Lung Cancer

Targeting HER2 genomic alterations in non-small cell lung cancer

Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022

Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data

Targeting KRAS in Non-Small Cell Lung Cancer